WO2006071603A3 - Phosphodiesterase 4d in the ryanodine receptor complex protects against heart failure - Google Patents
Phosphodiesterase 4d in the ryanodine receptor complex protects against heart failure Download PDFInfo
- Publication number
- WO2006071603A3 WO2006071603A3 PCT/US2005/045914 US2005045914W WO2006071603A3 WO 2006071603 A3 WO2006071603 A3 WO 2006071603A3 US 2005045914 W US2005045914 W US 2005045914W WO 2006071603 A3 WO2006071603 A3 WO 2006071603A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- ryanodine receptor
- disorders
- present
- diseases
- phosphodiesterase
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/04—Phosphoric diester hydrolases (3.1.4)
- C12Y301/04053—3',5'-Cyclic-AMP phosphodiesterase (3.1.4.53)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The present invention provides compositions useful for treating and preventing ryanodine receptor associated disorders comprising a PDE-associated agent and a pharmaceutically acceptable carrier. The present invention also provides methods for treating or preventing ryanodine receptor associated disorders including cardiac disorders and diseases, skeletal muscular disorders and diseases, cognitive disorders and diseases malignant hyperthermia, diabetes and sudden infant death syndrome. The present invention further provides methods for regulating PKA phosphorylation of a ryanodine receptor as well as methods for regulating Ca+2 release and reuptake in cells. Also provided are kits for use in delivering a PDE-associated agent to cardiac cells in a subject, comprising the composition of the present invention and a catheter.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002591924A CA2591924A1 (en) | 2004-12-16 | 2005-12-15 | Phosphodiesterase 4d in the ryanodine receptor complex protects against heart failure |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US63695904P | 2004-12-16 | 2004-12-16 | |
US60/636,959 | 2004-12-16 |
Publications (3)
Publication Number | Publication Date |
---|---|
WO2006071603A2 WO2006071603A2 (en) | 2006-07-06 |
WO2006071603A3 true WO2006071603A3 (en) | 2006-10-12 |
WO2006071603A9 WO2006071603A9 (en) | 2007-03-29 |
Family
ID=36615403
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2005/045914 WO2006071603A2 (en) | 2004-12-16 | 2005-12-15 | Phosphodiesterase 4d in the ryanodine receptor complex protects against heart failure |
Country Status (2)
Country | Link |
---|---|
CA (1) | CA2591924A1 (en) |
WO (1) | WO2006071603A2 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8710045B2 (en) | 2004-01-22 | 2014-04-29 | The Trustees Of Columbia University In The City Of New York | Agents for preventing and treating disorders involving modulation of the ryanodine receptors |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030054531A1 (en) * | 2001-03-19 | 2003-03-20 | Decode Genetics Ehf, | Human stroke gene |
US20040048780A1 (en) * | 2000-05-10 | 2004-03-11 | The Trustees Of Columbia University In The City Of New York | Method for treating and preventing cardiac arrhythmia |
WO2004042389A2 (en) * | 2002-11-08 | 2004-05-21 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with human phosphodiesterase 4d (pde4d) |
EP1439221A1 (en) * | 2002-12-17 | 2004-07-21 | F. Hoffmann-La Roche Ag | PDE core construct |
US20040224368A1 (en) * | 2003-03-07 | 2004-11-11 | Marks Andrew R. | Type 1 ryanodine receptor-based methods |
-
2005
- 2005-12-15 WO PCT/US2005/045914 patent/WO2006071603A2/en active Application Filing
- 2005-12-15 CA CA002591924A patent/CA2591924A1/en not_active Abandoned
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040048780A1 (en) * | 2000-05-10 | 2004-03-11 | The Trustees Of Columbia University In The City Of New York | Method for treating and preventing cardiac arrhythmia |
US20030054531A1 (en) * | 2001-03-19 | 2003-03-20 | Decode Genetics Ehf, | Human stroke gene |
WO2004042389A2 (en) * | 2002-11-08 | 2004-05-21 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with human phosphodiesterase 4d (pde4d) |
EP1439221A1 (en) * | 2002-12-17 | 2004-07-21 | F. Hoffmann-La Roche Ag | PDE core construct |
US20040224368A1 (en) * | 2003-03-07 | 2004-11-11 | Marks Andrew R. | Type 1 ryanodine receptor-based methods |
Non-Patent Citations (2)
Title |
---|
KAPILOFF MICHAEL S; JACKSON NICOLE; AIRHART NATHAN: "mAKAP and the ryanodine receptor are part of a multi-component signaling complex on the cardiomyocyte nuclear envelope", JOURNAL OF CELL SCIENCE, vol. 114, no. 17, September 2001 (2001-09-01), pages 3167 - 3176, XP002390984 * |
LEHNART STEPHAN E; WEHRENS XANDER H; REIKEN STEVEN R; JIN S -I C; VEST JOHN A; MARKS ANDREW R: "Phosphodiesterase 4D associates with the cardiac calcium release channel (Ryanodine receptor) and protects from hypertrophy and heart failure", CIRCULATION, vol. 110, no. 17SupplS, 26 October 2004 (2004-10-26), pages 227 - 228, XP009069565 * |
Also Published As
Publication number | Publication date |
---|---|
WO2006071603A2 (en) | 2006-07-06 |
WO2006071603A9 (en) | 2007-03-29 |
CA2591924A1 (en) | 2006-07-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2007004882A (en) | Xanthine derivatives with hm74a receptor activity. | |
CN104662007B (en) | Cystathionine gamma lyase (CSE) inhibitor | |
ES2630002T3 (en) | Anticancer drug containing alpha, alpha, alpha-trifluorothymidine and thymidine phosphorylase inhibitor | |
HRP20130406T1 (en) | Medicaments with hm74a receptor activity | |
WO2006070325A3 (en) | 2,3,4,9-tetrahydro-1h-carbazole derivatives as crth2 receptor antagonists | |
WO2006071778A3 (en) | Treatment of parkinson's disease and related disorders using postpartum derived cells | |
WO2006035237A3 (en) | Methods and compositions relating to alzheimer's disease | |
TN2009000137A1 (en) | Substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis | |
WO2006002361A3 (en) | 2-methylpropanamides and their use as pharmaceuticals | |
WO2001097786A3 (en) | Benzothiazole derivatives | |
WO2009082459A3 (en) | Anti-aging composition containing resveratrol and method of administration | |
WO2006122806A3 (en) | 1,3-dihydro-imidazo [4,5-c] quinolin-2-ones as lipid kinase inhibitors | |
WO2009106991A3 (en) | Pyridazine derivatives and their use as therapeutic agents in the treatment of skin disorders | |
GB0215844D0 (en) | Organic compounds | |
WO2005069865A3 (en) | Pyrrolopyrimidine derivatives and analogs and their use in the treatment and prevention of diseases | |
WO2009032870A3 (en) | Method to ameliorate oxidative stress and improve working memory via pterostilbene administration | |
MY142431A (en) | Oxadiazolones, processes for their preparation and their use as pharmaceuticals | |
MX2007004861A (en) | Novel sulphonamide derivatives as glucocorticoid receptor modulators for the treatment of inflammatory diseases. | |
MX2008001211A (en) | Benzylpiperazine derivates and their medical use. | |
EP4344743A2 (en) | Heterocyclic flavone derivatives, compositions, and methods related thereto | |
SG140605A1 (en) | Benzothiazole derivatives | |
WO2007042040A3 (en) | TREATMENT OF RETINOPATHIES USING GFRα3 AGONISTS | |
WO2006125194A3 (en) | Piperazine derivatives and their uses as therapeutic agents | |
WO2005009217A3 (en) | Diagnosis of pre-cancerous conditions using pcdgf agents | |
WO2006071603A3 (en) | Phosphodiesterase 4d in the ryanodine receptor complex protects against heart failure |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 2591924 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007546999 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
NENP | Non-entry into the national phase |
Ref country code: JP |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 05857129 Country of ref document: EP Kind code of ref document: A2 |